SequelSEC

Zivo Bioscience, Inc. ZIVO

Biological Products, (No Diagnostic Substances) · CIK 0001101026 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$65.62K
Fiscal year ended 2025-09-30
Operating income
-$1.02M
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

Valuation, from the filing

Public float$15.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-06-28
Float per share$4.15Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue99.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-28, not today, and each multiple below it uses the figures for the fiscal year ending 2024-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth468.6%92th
SBC / revenue961.1%89th
Current ratio0.80x15th
Net margin-8513.4%16th
Operating margin-8498.9%17th
Gross margin31.1%20th
R&D / revenue1994.0%73th

Zivo Bioscience, Inc. (ZIVO) reported revenue of $65.62K and net income of -$1.03M for the fiscal year ended 2025-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Zivo Bioscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Zivo Bioscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Revenue$65.62K$53.40K$0$90.00K$31.50K$0$35.72K$11.80K$11.80K$4.05K
Cost of revenue$44.34K$35.48K$0$63.00K$22.05K$0$23.22K$7.67K$7.67K$701
Gross profit$21.29K$17.92K$0$27.00K$9.45K$0$12.50K$4.13K$4.13K$3.35K
Operating income-$1.02M-$1.63M-$4.21M-$1.60M-$2.26M-$8.23M-$1.28M-$1.90M-$1.57M-$1.82M
Net income-$1.03M-$1.64M-$4.21M-$1.60M-$2.27M-$8.24M-$1.28M-$1.91M-$1.82M-$2.07M
Research & development$203.44K$479.66K$2.77M$243.48K$326.36K$2.25M$312.77K$312.46K$220.65K$442.11K
Weighted-average diluted sharesshares 3.82Mshares 3.81Mshares 3.75MUnavailableshares 3.41Mshares 2.96Mshares 2.75MUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable$0$0$0Unavailable$0$0
Diluted EPS$-0.27$-0.43$-1.12Unavailable$-0.67$-2.78$-0.47UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$836.19K$1.17M$1.44M$1.38M$1.94M$5.98M$975.57K$1.59M$1.36M$1.39M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Zivo Bioscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$559.45K$703.33K$1.33M$1.64M$495.59K$575.59K$816.40K$555.72K$2.10M$710.33K
Current assets$281.40K$409.89K$1.02M$1.64M$436.54K$495.13K$710.62K$425.38K$1.95M$530.08K
Total liabilities$3.85M$3.24M$2.95M$2.16M$2.58M$2.87M$3.09M$2.76M$3.20M$3.86M
Current liabilities$3.61M$2.96M$2.61M$2.04M$2.58M$2.87M$3.09M$2.76M$3.17M$3.80M
Total equity incl. NCI-$3.29M-$2.54M-$1.62M-$514.90K-$2.08M-$2.30M-$2.27M-$2.21M-$1.09M-$3.14M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$34.36K$0$2.21K$27.79K$0$3.74K$3.74K$2.59K$2.96K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$992.99K$860.94K$655.28K$547.09K$787.60K$1.09M$705.84K$993.09K$643.81K$1.27M

Cash flow

Zivo Bioscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Operating cash flow-$266.56K-$476.41K-$1.43M-$905.72K-$1.09M-$623.65K-$1.70M-$715.73K-$1.97M-$985.67K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$0$0$0$0$0$0$0$0$0
Financing cash flow$313.96K-$30.96K$404.98K$2.29M$1.24M$487.48K$1.56M-$494.53K$3.43M$798.13K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$621.16K$240.75K$227.81K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Zivo Bioscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin32.4%33.6%Unavailable30.0%30.0%Unavailable35.0%35.0%35.0%82.7%
Operating margin-1551.8%-3057.8%Unavailable-1773.8%-7174.7%Unavailable-3571.8%-16072.8%-13325.3%-45033.7%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-5264.1%UnavailableUnavailable
Current ratio0.08x0.14x0.39x0.80x0.17x0.17x0.23x0.15x0.61x0.14x
Revenue YoY growth108.3%Unavailable-100.0%662.7%166.9%-100.0%UnavailableUnavailableUnavailableUnavailable
Net margin-1574.2%-3071.6%Unavailable-1779.3%-7201.9%Unavailable-3579.2%-16174.1%-15465.4%-51125.2%
R&D / revenue310.0%898.2%Unavailable270.5%1036.1%Unavailable875.6%2648.0%1869.9%10916.4%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZIVO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-03-18View SEC filing
10-Q · Filed 2024-11-14View SEC filing
10-Q · Filed 2024-08-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.